This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | MicrobiomeTrials
← Back to trials NCT05556343
A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy TERMINATED PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-01-18Est. Completion: 2024-08-19
Enrollment target: 18 participantsLocations Local Institution - 0026, La Jolla, California, United States Local Institution - 0014, Los Angeles, California, United States Local Institution - 0016, San Francisco, California, United States Local Institution - 0001, Kansas City, Kansas, United States Local Institution - 0032, New York, New York, United States Local Institution - 0013, Durham, North Carolina, United States Local Institution - 0031, Cincinnati, Ohio, United States Local Institution - 0015, Cleveland, Ohio, United States Local Institution - 0024, Portland, Oregon, United States Local Institution - 0021, Nashville, Tennessee, United States Local Institution - 0025, San Antonio, Texas, United States Local Institution - 0006, Salt Lake City, Utah, United States Local Institution - 0027, Bologna, BO, Italy Local Institution - 0005, Florence, FI, Italy Local Institution - 0029, Milan, Italy Local Institution - 0011, Katowice, Silesian Voivodeship, Poland Local Institution - 0030, Wroclaw, Poland Other microbiome trials you might be interested in Hypertrophic Cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is a genetically mediated myocardial disease predominantly caused by pathogenic mutati…
Xi'an, China Est. completion Dec 31, 2030
Obstructive Hypertrophic Cardiomyopathy (oHCM)
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succi…
Anchorage, United States Completed Feb 28, 2025
Local Institution - 0028, Alicante, A, Spain
Local Institution - 0022, Granada, GR, Spain
Local Institution - 0008, Málaga, MA, Spain
Local Institution - 0002, El Palmar, MU, Spain
Local Institution - 0003, Valencia, V, Spain
Local Institution - 0009, A Coruña, Spain
Local Institution - 0023, Barcelona, Spain
Local Institution - 0010, Majadahonda, Spain The purpose of this study is to evaluate and compare the effectiveness of active screening for SHD in asymptomatic outpa…
Rochester, United States Est. completion Nov 2026